Laboratory of Cellular and Molecular Pathology of Cardiovascular System, Petrovsky National Research Center of Surgery, 119435 Moscow, Russia.
Laboratory of Medical Genetics, Chazov National Medical Research Center of Cardiology, 121552 Moscow, Russia.
Front Biosci (Landmark Ed). 2024 Jul 22;29(7):259. doi: 10.31083/j.fbl2907259.
Investigation of the inflammatory response of immune cells is a current focus of research on autoimmune disorders. The aim of this study was to evaluate the inflammatory status of monocytes/macrophages in systemic sclerosis (SSc).
The study included 35 SSc and 25 healthy participants. The secretion of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), monocyte chemoattractant protein-1 (MCP-1), interleukin-8 (IL-8), interleukin-6 (IL-6) was measured by enzyme-linked immunosorbent assay (ELISA) in primary cultures of monocytes/macrophages after stimulation with lipopolysaccharide (LPS) on day 1 and on day 6 of incubation. Impaired tolerance of the immune response was characterized by increased secretion of the inflammatory mediators in response to restimulation.
Basal secretion of all cytokines was significantly higher in SSc patients compared to healthy individuals. The secretion of TNF-α, IL-1β and IL-6 after the initial LPS stimulation, and secretion of IL-1β, MCP-1, IL-6, IL-8 after LPS restimulation, was significantly higher in the SSc group. Eleven SSc patients (31%) showed impaired immune tolerance in terms of MCP-1 secretion. These patients were significantly younger and had a higher level of anti-topoisomerase I (anti-Scl70) antibodies compared to SSc patients with immune tolerance.
This study revealed pro-inflammatory activation and impaired immune tolerance in monocytes/macrophages from SSc patients. The violation of immune response in terms of MCP-1 secretion may be an important factor in the development of chronic inflammation in SSc. MCP-1 may thus be a potential therapeutic target for novel SSc treatment strategies.
研究免疫细胞的炎症反应是当前自身免疫性疾病研究的重点。本研究旨在评估系统性硬化症(SSc)中单核细胞/巨噬细胞的炎症状态。
该研究纳入了 35 例 SSc 患者和 25 名健康对照者。在第 1 天和第 6 天孵育时,用脂多糖(LPS)刺激原代培养的单核细胞/巨噬细胞后,通过酶联免疫吸附试验(ELISA)测量肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、单核细胞趋化蛋白-1(MCP-1)、白细胞介素-8(IL-8)和白细胞介素-6(IL-6)的分泌。免疫反应的耐受性受损表现为炎症介质在再次刺激时分泌增加。
与健康个体相比,SSc 患者的所有细胞因子基础分泌均显著升高。初次 LPS 刺激后 TNF-α、IL-1β 和 IL-6 的分泌,以及 LPS 再刺激后 IL-1β、MCP-1、IL-6 和 IL-8 的分泌,在 SSc 组中均显著升高。11 例 SSc 患者(31%)在 MCP-1 分泌方面表现出免疫耐受受损。这些患者明显比具有免疫耐受的 SSc 患者年轻,且具有更高水平的抗拓扑异构酶 I(抗 Scl70)抗体。
本研究揭示了 SSc 患者单核细胞/巨噬细胞的促炎激活和免疫耐受受损。MCP-1 分泌方面的免疫反应异常可能是 SSc 慢性炎症发展的重要因素。因此,MCP-1 可能是 SSc 新型治疗策略的潜在治疗靶点。